Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Cardiol Therapeutics Inc (CRDL.TO)

Cardiol Therapeutics Inc (CRDL.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders

Toronto, Ontario--(Newsfile Corp. - June 27, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and...

CRDL : 2.13 (+2.40%)
CRDL.TO : 2.90 (+1.75%)
Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 p.m. EDT

Toronto, Ontario--(Newsfile Corp. - June 25, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and...

CRDL : 2.13 (+2.40%)
CRDL.TO : 2.90 (+1.75%)
Stocks in play: Cardiol Therapeutics Inc.

Added another feather to its cap last week with the announcement of its Phase II MAvERIC-Pilot study ...

CRDL.TO : 2.90 (+1.75%)
Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

Administration of CardiolRx™ led to a marked reduction in the primary efficacy endpoint of pericarditis painCardiolRx™ also shown to reduce inflammation in patients with elevated CRP89% of patients...

CRDL : 2.13 (+2.40%)
CRDL.TO : 2.90 (+1.75%)
Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024

Scope of presentation included trial design, rationale, and blinded baseline data on first 50 patients randomized into the Phase II study evaluating CardiolRx™ in patients with acute myocarditis ARCHER...

CRDL : 2.13 (+2.40%)
CRDL.TO : 2.90 (+1.75%)
Manufacturing, Housing Due Next Week in Canada

Monday U.S. Featured Earnings Legend Biotech Corporation (NASDAQ: LEGN) (Q1) EPS ...

CRDL.TO : 2.90 (+1.75%)
ORE.TO : 0.82 (+20.59%)
PBH.TO : 93.54 (+0.15%)
LEGN : 54.37 (+12.10%)
STNE : 13.47 (+0.37%)
PHVS : 18.77 (+2.91%)
BABA : 79.65 (+1.44%)
SONY : 96.07 (+0.46%)
CSCO : 47.38 (+1.33%)
TJX : 114.30 (+0.32%)
CPRT : 55.54 (+1.28%)
WMT : 69.24 (-0.80%)
How a Recent M&A Deal Could Catapult a Small-Cap Biotech to New Heights

Cardiol Therapeutics (CRDL), a clinical-stage life sciences company, is researching and developing new drugs to fight inflammation and scarring in the heart. Their main drug, CardiolRx™, is b

NVO : 142.08 (+1.64%)
CRDL : 2.13 (+2.40%)
CRDL.TO : 2.90 (+1.75%)
Cardiol Therapeutics Announces Year-End 2023 Update on Operations

Completed patient enrollment in the Phase II MAvERIC-Pilot study evaluating CardiolRx™ in patients withrecurrent pericarditis, with topline results expected in Q2 2024CardiolRx™ granted U.S. FDA Orphan...

CRDL : 2.13 (+2.40%)
CRDL.TO : 2.90 (+1.75%)
Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

Topline Results Expected in Q2 2024This is a Designated News Release.Toronto, Ontario--(Newsfile Corp. - February 21, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"),...

CRDL : 2.13 (+2.40%)
CRDL.TO : 2.90 (+1.75%)
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis

Designation Based on Pre-Clinical Data and Initial Clinical Data from the Company's MAvERIC-Pilot Phase II StudyThis is a Designated News Release.Toronto, Ontario--(Newsfile Corp. - February 15, 2024)...

CRDL : 2.13 (+2.40%)
CRDL.TO : 2.90 (+1.75%)

Barchart Exclusives

Analysts Still See Salesforce Stock As a Buy Here - Shorting OTM Puts Is a Good Play
Analysts still believe that Salesforce stock is undervalued, despite its recent runup. This is likely due to its strong free cash flow and FCF margins. Shorting out-of-the-money puts work well here. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar